New research suggests CCTA may provide salient preoperative insights into planning for percutaneous coronary intervention (PCI) while facilitating similar outcomes as intravascular ultrasound guidance for target-vessel failure.
|Articles|June 14, 2004
FDA clears handheld ultrasound
A new lightweight handheld ultrasound unit may soon be on the U.S. market. The FDA has cleared for sale the Mobilsonic VUE100, a low-cost device weighing less than three pounds. The system was developed by Mobilsonic and will be distributed in the U.S.
Advertisement
A new lightweight handheld ultrasound unit may soon be on the U.S. market. The FDA has cleared for sale the Mobilsonic VUE100, a low-cost device weighing less than three pounds. The system was developed by Mobilsonic and will be distributed in the U.S. by Bierley Ultrasound.
Advertisement
Related to this article
Catch up on a variety of FDA news in radiology from the past week.
Facilitating enhanced 3D visualization of skeletal anatomy, the BoneEnhance machine learning module reportedly provides automated segmentation of bone and surrounding tissues for the Accuro XV ultrasound system.
A Kaiser score > 5 with breast MRI demonstrated a 97 percent sensitivity and 87.9 percent specificity for predicting malignancy in patients with BI-RADS 0 or 4 presentations on mammography and breast ultrasound, according to a new study.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Key Features with EPNI on CT May More than Double Mortality Risk in Pancreatic Cancer
2
Top Five Radiology Content in October 2026
3
Could a CCTA-Guided Approach Provide a Viable Alternative to Intravascular Ultrasound Guidance for PCI Procedures?
4
Simple for a Radiologist, Complex for Everyone Else
5